implement in the portfolio: 1. Take advantage of the sell-off in Healthcare by buying 3 large cap pharma names. Name Ticker Rating JPM Target Merck & Co., Inc. MRK OW $66 Pfizer Inc. PFE OW $40 Bristol-Myers Squibb Co. BMY OW $78 Source: Bloomberg 10/07/2015 2. Nikkei 400 linked structure

• Lead or Co-manager: I. Morgan acted as lead or co-manager in a public offering of equity andfor debt securities for Bristol-Myers Squibb Coin any, Merck & Co., Inc. within the past 12 months. li • Client: . Morgan currently has, or had within the past 12 months, the following company(ies) as clients: Bris

cals business from 2000 to 2003. Prior to joining SmithKline Beecham plc Mr. Pien worked for six years at Abbott Laboratories and for five years at Merck & Co. Mr. Pien is also a director of Vanda Pharmaceuticals and ViroPharma Incorporated. DACAR 1 CAPIIAL LLC EFTA00506153 References • Michael Eisenso

cals business from 2000 to 2003. Prior to joining SmithKline Beecham plc Mr. Pien worked for six years at Abbott Laboratories and for five years at Merck & Co. Mr. Pien is also a director of Vanda Pharmaceuticals and ViroPharma Incorporated. DACAR 1 CAPIIAL LLC EFTA00506199 Advisory Board Andreas Breme

both Plaintiffs and Defendants cite cases where courts confirmed fee rates similar to the ones they seek. See, e.g, ECF No. 105 at 10 (citing In re Merck & Co. Vytorin ERISA Litig., 2010 U.S. Dist. LEXIS 12344, 2010 WL 547613 (D.N.J. Feb. 9, 2010) (approving rates up to $835 per hour)); ECF No. 90 at 10 (c

both Plaintiffs and Defendants cite cases where courts confirmed fee rates similar to the ones they seek. See, e.g, ECF No. 105 at 10 (citing In re Merck & Co. Vytorin ERISA Litig., 2010 U.S. Dist. LEXIS 12344, 2010 WL 547613 (D.N.J. Feb. 9, 2010) (approving rates up to $835 per hour)); ECF No. 90 at 10 (c

cals business from 2000 to 2003. Prior to joining SmithKline Beecham plc Mr. Pien worked for six years at Abbott Laboratories and for five years at Merck & Co. Mr. Pien is also a director of Vanda Pharmaceuticals and ViroPharma Incorporated. DACART CAPITAL LLC EFTA_R1_01138848 EFTA02295574 References